Generated by All in One SEO Pro v4.9.10, this is an llms.txt file, used by LLMs to index the site. # MEDVANCE THINK GLOBAL, ACT LOCAL ## Sitemaps - [XML Sitemap](https://medvance.eu/sitemap.xml): Contains all public & indexable URLs for this website. ## Posts - [« The goal of IHI is to tackle challenging unmet public health needs that can only be addressed by cross-sector collaboration »](https://medvance.eu/the-goal-of-ihi-is-to-tackle-challenging-unmet-public-health-needs-that-can-only-be-addressed-by-cross-sector-collaboration/) - [AIFA - Impact of simplified procedures introduced in 2020 on the negotiation of medicinal products](https://medvance.eu/aifa-impact-of-simplified-procedures-introduced-in-2020-on-the-negotiation-of-medicinal-products/) - [Webinar : What does the Brexit effect mean for UK patient access?](https://medvance.eu/webinar-what-does-the-brexit-effect-mean-for-uk-patient-access/) - Join our webinar : What does the Brexit effect mean for UK patient access? on march 29 2022. - [What changes to NICE’s health technology evaluation are now in effect?](https://medvance.eu/what-changes-to-nices-health-technology-evaluation-are-now-in-effect/) - From 1st February 2022, the National Institute for Health and Care Excellence (NICE) will introduce changes that aim to simplify and speed up Health Technology Assessments (HTA). - [Webinar Replay: AMNOG impact on European countries?!](https://medvance.eu/webinar-replay-amnog-impact-on-european-countries/) - Watch our webinar replay : AMNOG impact on European countries?! Dr. Stefan Walzer discussed this issue together with country experts across Europe. - [The new Italian Law on Rare disease : access to orphan drugs, support for research, solidarity fund.](https://medvance.eu/the-new-italian-law-on-rare-disease-access-to-orphan-drugs-support-for-research-solidarity-fund/) - On 27 November 2021, Law No. 175/2021, was published in the Official Journal. This is the first law dedicated exclusively to rare diseases. It's main objective is the protection of the right to health of those suffering from rare diseases. ## Pages - [Home](https://medvance.eu/) - Medvance is an economic interest group made up of independent consulting firms offering tailor-made solutions with access problems to European healthcare markets. - [Home](https://medvance.eu/) - Medvance is an economic interest group made up of independent consulting firms offering tailor-made solutions with access problems to European healthcare markets. - [About](https://medvance.eu/about/) - Medvance is a legal entity that promotes the collaboration of specialised consultancy firms across Europe in terms of Market access and Public affairs. - [Publications](https://medvance.eu/publications/) - All the publications presented by Medvance's experts during their participation in international Healthcare and pharmaceutical Market Access conferences such as ISPOR Europe. - [Services](https://medvance.eu/services/) - Medvance conceptualizes, creates and coordinates projects in two areas of expertise: Market Access and Public Affairs for Phamarceutical instituteand Health professionals - [Publications 2021](https://medvance.eu/publications-2021/) - Discover all our 2021 publications on health and health regulations - [Publications 2023](https://medvance.eu/publications-2023/) - You can find all our publications for the year 2023 - [Publications 2022](https://medvance.eu/publications-2022/) - Discover all our 2022 publications on health and health regulations - [Publications 2020](https://medvance.eu/publications-2020/) - Find all the 2020 publications presented by Medvance's experts in terms of New digital health application, Healthcare market Access, Health Economics,... - [Publications 2019](https://medvance.eu/conference-2019/) - Find all the 2019 publications presented by Medvance's experts in terms of International Healthcare Market Access, Health policy and insurance,... - [Publications 2018](https://medvance.eu/publications-2018/) - 2018 IPSOR conference : Price differences for orphan drugs across the european healthcare market and reimbursement decisions. - [Contact](https://medvance.eu/contact/) - To learn more about MEDVANCE services and receive advices from our Healthcare Market Access and Public Affairs' experts, we invite you to connect with a team member - [Business cases](https://medvance.eu/business-cases/) - [Blog](https://medvance.eu/blog/) - Medvance Blog ## Business Cases - [Modele par defaut](https://medvance.eu/business_cases/test-1/) ## Board Members - [GUILLAUME BOUCHARA](https://medvance.eu/board-members/guillaume-bouchara/) - Guillaume founded Nextep in 1999, a leading consultancy is Market Access and Public Affairs. Executive Secretary General, he started his career in consulting. - [MARIANGELA PRADA](https://medvance.eu/board-members/mariangela-prada/) - Mariangela Prada has 20 years of experience in the development and execution of healthcare market access programs. - [GRAHAM FOXON](https://medvance.eu/board-members/graham-foxon/) - Graham co-founded Remap Consulting in 2014 with the mission to help clients optimise their pricing, health economics and market access outcomes. - [VINCENT CHENEY](https://medvance.eu/board-members/vincent-cheney/) - Vincent Cheney joined the pharmaceutical division, responsible for marketing operations in France and Belgium, in 1996 and joined Nextep as partner in charge of international development in 2017. - [DR.STEFAN WALZER](https://medvance.eu/board-members/dr-stefan-walzer/) - Stefan founded MArS in 2012, specialized in market access, reimbursement, health economics and pricing strategies on the German-speaking markets.